<DOC>
	<DOCNO>NCT00666835</DOCNO>
	<brief_summary>This double-blind , randomize , multicenter , parallel-group , equivalence study involve 462 clinically stable hemodialysis patient age 18 year suffer anemia treat previously stable dose ERYPO® intravenously .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety HX 575 v ERYPO® Treatment Anemia Hemodialysis Patients</brief_title>
	<detailed_description>The primary objective Phase III study evaluation therapeutic equivalence HX575 comparator epoetin alfa maintenance intravenous treatment renal anemia . Efficacy , dosage safety HX575 long-term treatment assess .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Receiving dialysis least 6 month ( 3 time weekly ) screen Age : &gt; =18 Clinically stable , i.e . hemoglobin within establish range ( 10.0 13.0 g/dl ) least 12 week screen Stable intravenous dosage ERYPO® three time weekly least 8 week screen screen maximal weekly dosage 300 IU/kg body weight ( stable define &lt; 25 % change ( ) weekly dose change frequency 8 week prior screen 10 week prior randomisation ) Baseline hemoglobin concentration 10.0 13.0 g/dl ( mean two prerandomization predialysis sample Hb visit 2 visit 1 ) Serum ferritin &gt; =100 µg/l and/or saturate transferrin level &gt; =20 % Creactive protein &lt; 15 mg/l ( &lt; 5 mg/l : normal ; &gt; = 5 mg/l &lt; 10 mg/l : + ; &gt; =10mg/l &lt; 100 mg/l : ++ ; &gt; =100 mg/l : +++ ) Ability follow study instruction likely complete require visit Written inform consent patient Anemia nonrenal cause Primary hematologic disorder ( e.g . myelodysplastic syndrome , sickle cell anemia , hematological malignancy , hemolytic anemia ) Evidence severe hepatic dysfunction ( ALT and/or AST 2 x upper limit normal range ; gammaGT 3 x upper limit normal range ) Clinical evidence current uncontrolled hyperparathyroidism ( serum parathyroid hormone &gt; 1500 pg/mL ) . Known history bone marrow disease Any red blood cell transfusion ( ) last 12 week screen screening/baseline period Insufficient concomitant iron treatment last 2 month Visit 2 Uncontrolled hypertension , define predialysis diastolic blood pressure measurement &gt; =110 mmHg screen period Congestive heart failure [ New York Heart Association ( NYHA ) class III IV ] Unstable angina pectoris , active cardiac disease , cardiac infarction last six month screen History blood coagulation disease Thrombocytopenia ( platelet count &lt; 100.000/µl ) Leukopenia ( white blood cell count &lt; 2.000/µl ) Overt bleeding ( acute chronic bleeding within 2 month inclusion ) hemolysis Evidence acute infectious disease serious active inflammatory state within one month screen ( Visit 2 ) screening/baseline period Suspicion know PRCA ( pure red cell aplasia ) Previously diagnose HIV acute hepatitis infection Treatment epilepsy within past 6 month Planned surgery next 7 month ( except vascular access surgery ) Any androgen therapy within 2 month visit 2 study Therapy immunosuppressant drug know affect hematocrit within 1 month Visit 2 study Clinical evidence malignant diseases Pregnancy , breastfeed woman woman use adequate birth control measure Known history severe drug related allergy Known allergy one ingredient test reference product hypersensitivity mammalianderived product Simultaneous participation another clinical study participation study month precede start study previously randomize study Participation erythropoietin study 3 month precede screening ( visit 2 ) Any condition investigator´s discretion may put patient risk may confound study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Treatment anemia hemodialysis patient</keyword>
</DOC>